ASH: Pfizer’s Hemophilia A Gene Therapy May Have Slight Liver Safety Advantage
More Data Needed For Longer-Term Effects
Hematologists’ concerns about hepatoxicity with hemophilia A gene therapies may limit use, but Phase III data for Pfizer’s candidate at ASH show a lower rate of ALT increases than seen with BioMarin’s Roctavian.
